Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world.
Front Pharmacol
; 15: 1444169, 2024.
Article
in En
| MEDLINE
| ID: mdl-39234112
ABSTRACT
Objectives:
Olanzapine is used for treating bipolar disorder (BPD); however, the optimal initial dosing regimen is unclear. The present study aimed to investigate the optimal olanzapine initial dosage in patients with BPD via model-informed precision dosing (MIPD) based on a real-world study.Methods:
Thirty-nine patients with BPD from the real-world study were collected to construct the MIPD model.Results:
Weight, combined used quetiapine influenced olanzapine clearances in patients with BPD, where the clearance rates were 0.1521 in patients with or without quetiapine under the same weight. We simulated olanzapine doses once a day or twice a day, of which twice a day was optimal. Without quetiapine, for twice-a-day olanzapine doses, 0.80, 0.70, and 0.60 mg/kg/day were suitable for 40- to 56-kg BPD patients, 56- to 74-kg BPD patients, and 74- to 100-kg BPD patients, respectively. With quetiapine, for twice-a-day olanzapine doses, 0.05 mg/kg/day was suitable for 40- to 100-kg BPD patients.Conclusion:
This study was the first to investigate the optimal olanzapine initial dosage in patients with BPD via MIPD based on a real-world study, providing clinical reference for the precision medication of olanzapine in BPD patients.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Pharmacol
/
Frontiers in pharmacology
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: